Morgan Stanley’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-809,248
| Closed | -$27.9M | – | 7278 |
|
|
2020
Q3 | $27.9M | Buy |
809,248
+453,795
| +128% | +$9.66M | 0.01% | 1240 |
|
|
2020
Q2 | $5.94M | Sell |
355,453
-663,239
| -65% | -$11.3M | ﹤0.01% | 2491 |
|
|
2020
Q1 | $14.7M | Buy |
1,018,692
+466,231
| +84% | +$11.9M | ﹤0.01% | 1497 |
|
|
2019
Q4 | $18.5M | Buy |
552,461
+66,565
| +14% | +$1.86M | ﹤0.01% | 1732 |
|
|
2019
Q3 | $10.2M | Sell |
485,896
-259,294
| -35% | -$5.29M | ﹤0.01% | 2105 |
|
|
2019
Q2 | $15.5M | Sell |
745,190
-3,097
| -0.4% | -$63.8K | ﹤0.01% | 1718 |
|
|
2019
Q1 | $16.7M | Sell |
748,287
-184,024
| -20% | -$4.33M | ﹤0.01% | 1582 |
|
|
2018
Q4 | $22.3M | Sell |
932,311
-12,977
| -1% | -$336K | 0.01% | 1375 |
|
|
2018
Q3 | $25.8M | Sell |
945,288
-13,516
| -1% | -$382K | 0.01% | 1455 |
|
|
2018
Q2 | $25.8M | Buy |
958,804
+242,895
| +34% | +$7.43M | 0.01% | 1414 |
|
|
2018
Q1 | $22.8M | Buy |
715,909
+68,008
| +10% | +$2.39M | 0.01% | 1551 |
|
|
2017
Q4 | $24.5M | Buy |
647,901
+3,615
| +0.6% | +$117K | 0.01% | 1494 |
|
|
2017
Q3 | $16M | Buy |
644,286
+65,832
| +11% | +$1.42M | ﹤0.01% | 1790 |
|
|
2017
Q2 | $11.9M | Buy |
578,454
+122,143
| +27% | +$2.33M | ﹤0.01% | 2011 |
|
|
2017
Q1 | $9.92M | Buy |
456,311
+127,700
| +39% | +$2.62M | ﹤0.01% | 2204 |
|
|
2016
Q4 | $6.72M | Buy |
328,611
+92,181
| +39% | +$1.88M | ﹤0.01% | 2682 |
|
|
2016
Q3 | $3.55M | Buy |
236,430
+36,461
| +18% | +$492K | ﹤0.01% | 3002 |
|
|
2016
Q2 | $2.16M | Buy |
199,969
+177,330
| +783% | +$2.41M | ﹤0.01% | 3359 |
|
|
2016
Q1 | $307K | Buy |
22,639
+17,812
| +369% | +$278K | ﹤0.01% | 4720 |
|
|
2015
Q4 | $89K | Buy |
4,827
+4,527
| +1,509% | +$83.7K | ﹤0.01% | 5471 |
|
|
2015
Q3 | $8K | Buy |
+300
| New | +$7.01K | ﹤0.01% | 6307 |
|
Morgan Stanley's AIMT Position: Q4 2020 in Review
Morgan Stanley sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 809,248 shares — an estimated $27.9M sold.
Morgan Stanley first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $27.9M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Morgan Stanley reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Morgan Stanley sold 809,248 Aimmune Therapeutics shares in Q4 2020, an estimated $27.9M.
- Morgan Stanley first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Morgan Stanley's Aimmune Therapeutics position peaked at $27.9M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Morgan Stanley's 13F filing for Q4 2020, filed 16 Feb 2021.